Inside Fabian Gerlinghaus' Cellares and their $380M push to automate cell therapy manufacturing
With Bridgewater online and global facilities underway, Cellares is moving from platform development to commercial execution. CEO Fabian Gerlinghaus says, “Our factories can produce as many therapies as ten manual facilities - with just ten percent of the people.”
